BridgeBio Pharma
Update in progressBBIO (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
BridgeBio Pharma discovers and develops medicines for genetic diseases. Its programs include Attruby, a TTR stabilizer for ATTR-CM; Fosdenopterin (NULIBRY) for molybdenum cofactor deficiency; low-dose infigratinib for achondroplasia and hypochondroplasia; Encaleret for Autosomal Dominant Hypocalcemia Type 1 and Chronic Hypoparathyroidism; BBP-418 for LGMD2I; and BBP-812 AAV gene therapy for Canavan disease. It partners with Bayer, Alexion, Stanford, and Novartis. Founded 2015, Palo Alto.
Company score
- Sentiment
- 0.93
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.01
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.94
- Governance
- 0.20
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.32
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.63
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!